Search Medical Condition
Please enter condition
Please choose location from dropdown

Pulmonary Arterial Hypertension Clinical Trials

A listing of Pulmonary Arterial Hypertension medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (193) clinical trials

The purpose of this study is to assess the clinical use of the UltraScore balloon. In order to be in this study, you must be willing to be available for follow-up visits at your doctor’s office at 30-days and 6- and 12-months after your procedure.  

Phase N/A

The purpose of this study is to evaluate the efficacy and safety of intermittent levosimendan compared with placebo in hemodynamic improvement with exercise in PH-HFpEF subjects  

Phase

This is a multicenter, randomized (1:1; oral treprostinil to placebo), double-blind, placebo-controlled study in subjects with World Health Organization (WHO) Group 2 pulmonary hypertension (PH) associated with heart failure with preserved ejection fraction (HFpEF). Once randomized, subjects will take the initial dose of study drug at the study site on ...

Phase

People with Pulmonary Arterial Hypertension are asked to participate in a research study being conducted by North Shore University Hospital.

Phase N/A

NYU Winthrop Hospital Clinical Trials Center is conducting this clinical research study for patients between the ages of 18 and 85 years old, who have been diagnosed with PAH. Pulmonary Arterial Hypertension occurs when the pressure in the pulmonary artery (the blood vessel that leads from the heart to the ...

Phase N/A

The primary objective of this study is to assess the effect of oral treprostinil compared with placebo on change in exercise capacity as measured by change in 6MWD from Baseline to Week 24 in subjects with PH associated with HFpEF. There are no approved treatments for PH in subjects with ...

Phase

Prospective Non-interventional Multi-center Post-authorization Safety Study of Riociguat for Pulmonary Arterial Hypertension (PAH)

This local, prospective, non-interventional, multi-center study includes patients treated with Riociguat for PAH. A total of 600 patients (valid for safety analysis) is planned to be included in 4 years. This study is performed as an "all-case investigation" therefore; all patients who receive Riociguat treatment for PAH need to be ...

Phase N/A

Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension

The primary objective for this trial is to evaluate the safety and tolerability of GB002. The secondary objective for this trial is to evaluate the PK parameters of GB002. Exploratory objectives are to evaluate the PD and biomarkers readouts, change in WHO Group I functional class, and change in quality ...

Phase

Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is characterized by progressive loss of function by the pulmonary vascular bed due to a variety of factors including obliterative vascular lesions, vasoconstriction, and thrombotic occlusion of the pulmonary arteries. Ultimately, right-sided heart failure ensues with severe limitation of exercise and eventual progression to death or ...

Phase

A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.

To provide riociguat therapy to eligible patients with PAH originating from Bayer-sponsored trials with BAY63-2521/ Riociguat / Adempas who are currently or recently treated in these trials until lack of patient benefit as assessed by investigator, or commercial availability and reimbursement.

Phase